Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK92MI + HS20
- Development stage
- Preclinical
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NK92MI + HS20 is a genetically engineered combination cell therapy product consisting of NK92MI cells expressing a chimeric antigen receptor (CAR) based on the HS20 single-chain antibody fragment, which specifically targets glypican-3 (GPC3), a surface antigen highly expressed in hepatocellular carcinoma (HCC). The HS20 antibody recognizes the heparan sulfate chains present on GPC3. The CAR construct includes a human IgG1 hinge, CD28 transmembrane and intracellular domains, 4-1BB intracellular domain, and CD3zeta intracellular domain. The therapy is designed to enhance the cytotoxicity of natural killer (NK) cells against GPC3-positive tumor cells, aiming for targeted immunotherapy in HCC.
- Other names
- CAR-NK92MI-HS20CAR-NK-92MI-HS20CAR-NK 92MI-HS20CAR-NK92MI/HS20
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on NK92MI + HS20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK92MI + HS20.